Innovative Therapies for Neurodegenerative Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 30 November 2025
Special Issue Editors
Interests: biotechnology; biochemistry; neurodegeneration and related diseases
Special Issues, Collections and Topics in MDPI journals
Interests: neurotoxicity; cognitive disorders; cancer; natural products; drug targeting strategies
Special Issues, Collections and Topics in MDPI journals
Interests: bioactive compounds; cell signaling; drug delivery; drug discovery; enzymology; high-throughput screening; metalloproteases; molecular pharmacology; nanoparticles; neuropeptides; neurodegenerative diseases; parkinson's disease; protein-protein interaction inhibitors; protein engineering; protein structure; protease inhibitors; protein folding and aggregation; substrate specificity; X-ray crystallography
Special Issues, Collections and Topics in MDPI journals
Interests: drug delivery; targeted therapy; brain delivery; brain cancer; glioblastoma; cancer therapy; neurodegenerative disease therapy; biophysical models; drug–membrane interactions
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS) present significant medical challenges due to their irreversible progression and lack of curative treatments. In recent years, “innovative therapies” have emerged with the goal of not only alleviating symptoms but also modifying disease progression.
Neurodegenerative diseases have driven the exploration of innovative therapies, including nanotechnology, cellular therapy, gene therapy, and new pharmacological approaches. Nanotechnology enables the development of nanoparticles capable of crossing the blood-brain barrier, facilitating the direct delivery of drugs to affected neurons. Cellular and regenerative strategies involve the use of stem cells, direct and partial cellular reprogramming to restore neuronal function. Gene therapy and RNA interference have allowed for the modification of gene expression related to neurodegeneration, silencing those that contribute to the accumulation of toxic proteins in the brain. Additionally, new protein aggregation inhibitors, neuroinflammation modulators, and drugs targeting mitochondrial dysfunction have been developed to enhance energy production in neurons. These strategies represent significant advances in the fight against diseases such as Alzheimer’s and Parkinson’s, although further clinical trials are needed to validate their safety and efficacy.
The Special Issue of Pharmaceutics welcomes submissions on the following topics: pharmacological approaches, cellular therapies, nanotechnology, and neuroprotection strategies. The Special Issue of Biomedicines welcomes submissions focusing on molecular and cellular mechanisms underlying these diseases and therapeutic approaches. We invite researchers and healthcare professionals to submit their original studies or review articles with expert insights and perspectives in the field of therapeutic neuroscience.
Dr. Rosa María Giráldez-Pérez
Dr. María Victoria Naval
Dr. Javier Garcia-Pardo
Dr. Maria João Ramalho
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotechnology-based therapies
- cellular and regenerative therapies
- stem cell therapy
- gene therapy and RNA interference
- protein aggregation inhibitors
- neuroinflammation modulators
- mitochondrial dysfunction-targeted drugs
- preclinical and clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
